STAT+: A Supreme Court review of a contentious patent issue would change the way pharma claims discoveries
In the coming weeks, the Supreme Court is expected to decide whether to review a…
Category: Pharmaceuticals
Opinion: FDA rule would facilitate prescription-to-OTC switches but nix a third class of drugs
After a decade-long wait, the Food and Drug Administration finally issued a proposed rule in…
Opinion: STAT+: How pharma and biotech can keep innovating in a bear market
Over the last decade, the biotech sector experienced the largest boom it has ever seen….
STAT+: Drug companies will have to start refunding Medicare for certain drugs that get thrown out
Starting next year, pharmaceutical companies will have to repay Medicare for any unused amount of drugs…
.jpg)
Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate
Is the era of the unicorn over? What’s gotten into the FDA? And will a…
Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need
America’s economically disadvantaged patients can point in two directions when talking about what is wrong…
Doctors are clamoring for more clarity on Paxlovid prescribing amid Covid-19 rebound concerns
Six months after regulators issued an emergency use authorization for Paxlovid, physicians say they still…
STAT+: The biotech scorecard for the third quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: The near-term outlook for pharma industry earnings just got a little worse
The near-term earnings outlook for the pharmaceutical industry was revised downward by a major credit…
Democrats tweak their drug pricing plan in last-ditch effort to pass reforms
WASHINGTON — Senate Democrats are vetting a new, tweaked version of a drug pricing package as…
STAT+: 100 lawmakers ask HHS to use controversial federal laws to combat high drug prices
A group of 100 federal lawmakers is urging the Biden administration to use controversial provisions…
STAT+: Pharma largely failed to follow human rights principles with its Covid-19 vaccines and drugs
More than two years after the Covid-19 pandemic emerged, a new scorecard finds that 19…
STAT+: Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs
Three years ago, a former CVS Health executive told a U.S. Senate committee hearing that…
STAT+: Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds
In response to rising prices for medicines, public and private payers increasingly rely on assessments…
STAT+: Pharmalittle: U.K. inks $1.2 billion deal with Moderna for vaccine center; Top Biocon exec arrested in bribery scandal
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate
Amid concerns that patent reviewers disregard competitive effects on prescription drugs, a bipartisan group of…
STAT+: European researchers seek greater stake in drug development in bid to improve access
As the price of new medicines weighs on health payers in Europe, universities are seeking…
STAT+: European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market
The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information…
STAT+: Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs
Good morning, everyone, and welcome to another working week, although today is actually a holiday…
STAT+: A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease
Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment…
STAT+: Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival
Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may…
STAT+: Pharmalittle: Canada OKs ALS drug still waiting FDA approval; WTO talks on Covid patent waiver are down to the wire
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: Pursuit of profits is driving drug companies to break the 340B law
Seventeen drug companies, including some of the world’s largest, are flouting a 30-year-old federal program…
STAT+: FTC will investigate pharmacy benefit managers and their role in prescription drug costs
After months of deliberation, the U.S. Federal Trade Commission has voted unanimously to investigate several…
Opinion: FDA user fee legislation needs to mitigate the pharmaceutical industry’s carbon pollution
As Congress works to reauthorize for the seventh time pharmaceutical user fee legislation, it is…
Opinion: It’s time to move past Aduhelm and focus on a broader Alzheimer’s drug pipeline
When Alzheimer’s disease was believed to be caused solely by the accumulation of amyloid protein…
STAT+: Roche’s Tigit troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target
CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in…
STAT+: Companies can’t make CAR-T cells for cancer treatment quickly enough. Here’s what they’re doing about it
The shortage of manufacturing slots for CAR-T cells, which has left myeloma patients dying on…
‘How do you decide?’: Cancer treatment’s CAR-T crisis has patients dying on a wait list
Within two years of being diagnosed with multiple myeloma, Shawn Goltzene had blasted through nearly…
STAT+: While a law designed to thwart counterfeit medicines lurches into full force, fake pills keep circulating
As far as Shane Jerominski was concerned, the many bottles of a widely used HIV…
Coronavirus hasn’t developed resistance to Paxlovid. How long can that last?
When the patient came back 10 days later, coughing repeatedly and complaining of headache, Davey…
Opinion: STAT+: QR codes can help pharmaceutical companies in two big ways
QR codes, which had begun a fall into obscurity, have come roaring back. Many restaurants…
STAT+: Pfizer will sell its patent-protected medicines and vaccines to poor countries at low prices
In an ambitious move to widen access to its medical products, Pfizer said Wednesday that…
As reports of ‘Paxlovid rebound’ increase, Covid researchers scramble for answers
As he was treating some of the nation’s first coronavirus patients, Andre Kalil noticed something…
STAT+: Pfizer to refund $290,000 to consumers in four states over misleading copay couponds
Amid controversy over the use of patient coupons, Pfizer has agreed to refund $290,000 to…
STAT+: European regulator suspends generic drugs after finding flawed studies
In the latest dust-up over the safety of medicines, the European Medicines Agency recommended suspending…
STAT+: AbbVie dramatically boosts its spending on lobbying
WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three…
STAT+: Pharma wins a court battle over an HHS rule that would have penalized them for offering copay coupons
In a notable win for the pharmaceutical industry, a federal court judge tossed a rule…
STAT+: ‘Pharma bro’ Martin Shkreli released from prison
Martin Shkreli, the infamous ‘pharma bro’ who was sentenced to prison for securities fraud, was…
Opinion: Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!
As a primary care doctor in New York City, I am grateful to drug companies…
STAT+: Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds
For more than three decades, drugmakers have used various tactics to win and extend monopolies…
STAT+: High blood pressure pills are costly — but also hard to find — in some lower-income countries
A clutch of serious challenges — high prices, a lack of effective combination pills, and…
STAT+: Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Two dozen states have waded into the heated dispute between the U.S. government and a…
STAT+: Greece plans to go to court to seek compensation from Novartis over a bribery scandal
The Greek health ministry plans to seek compensation from Novartis over a long-running bribery scandal…
STAT+: Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Senate FDA legislation will include dietary supplement, cosmetic reforms
WASHINGTON – Senate lawmakers are set to unveil draft legislation as soon as Monday that…
Opinion: A consultant wrote the playbook on drug pricing — then distanced himself from it
When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company…